Literature DB >> 23467932

Exacerbated autoimmunity in the absence of TLR9 in MRL.Fas(lpr) mice depends on Ifnar1.

Kevin M Nickerson1, Jaime L Cullen, Michael Kashgarian, Mark J Shlomchik.   

Abstract

TLR9 suppresses TLR7-driven pathogenesis in the MRL.Fas(lpr) murine model of systemic lupus erythematosus, but the mechanisms by which TLR7 promotes and TLR9 prevents disease in this and other lupus models remain unclear. Type I IFNs (IFN-I) have also been implicated in the pathogenesis of lupus both in patients and in several murine models of disease, but their role in MRL.Fas(lpr) mice is controversial. Using MRL.Fas(lpr) mice genetically deficient in a subunit of the receptor for IFN-I, Ifnar1, we show that IFN-I contribute significantly to renal disease in this model. Ifnar1 had no effect on anti-nucleosome or anti-Sm autoantibody titers, but instead regulated anticytoplasmic and anti-RNA specificities. Moreover, Ifnar1 deficiency prevented the exacerbation of clinical disease observed in Tlr9-deficient animals in this lupus model. Thus, IFN-I signaling is an important mediator of lupus pathogenesis and anti-RNA Ab production that is dysregulated in the absence of Tlr9.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23467932      PMCID: PMC3622185          DOI: 10.4049/jimmunol.1203525

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

Review 1.  Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease.

Authors:  Anna-Marie Fairhurst; Amy E Wandstrat; Edward K Wakeland
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

2.  Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.

Authors:  Hannes Cash; Manfred Relle; Julia Menke; Christoph Brochhausen; Simon A Jones; Nicholas Topley; Peter R Galle; Andreas Schwarting
Journal:  J Rheumatol       Date:  2009-12-01       Impact factor: 4.666

3.  TLR9 regulates TLR7- and MyD88-dependent autoantibody production and disease in a murine model of lupus.

Authors:  Kevin M Nickerson; Sean R Christensen; Jonathan Shupe; Michael Kashgarian; Daniel Kim; Keith Elkon; Mark J Shlomchik
Journal:  J Immunol       Date:  2010-01-20       Impact factor: 5.422

4.  Critical role of TLR7 in the acceleration of systemic lupus erythematosus in TLR9-deficient mice.

Authors:  Marie-Laure Santiago-Raber; Isabelle Dunand-Sauthier; Tianfu Wu; Quan-Zhen Li; Satoshi Uematsu; Shizuo Akira; Walter Reith; Chandra Mohan; Brian L Kotzin; Shozo Izui
Journal:  J Autoimmun       Date:  2009-11-26       Impact factor: 7.094

5.  Deficiency of the type I interferon receptor protects mice from experimental lupus.

Authors:  Dina C Nacionales; Kindra M Kelly-Scumpia; Pui Y Lee; Jason S Weinstein; Robert Lyons; Eric Sobel; Minoru Satoh; Westley H Reeves
Journal:  Arthritis Rheum       Date:  2007-11

6.  Type I interferon signaling is involved in the spontaneous development of lupus-like disease in B6.Nba2 and (B6.Nba2 x NZW)F(1) mice.

Authors:  T N Jørgensen; E Roper; J M Thurman; P Marrack; B L Kotzin
Journal:  Genes Immun       Date:  2007-09-20       Impact factor: 2.676

Review 7.  Development of TLR inhibitors for the treatment of autoimmune diseases.

Authors:  Franck J Barrat; Robert L Coffman
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

8.  Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease.

Authors:  Hemant Agrawal; Noam Jacob; Esther Carreras; Sandra Bajana; Chaim Putterman; Sean Turner; Barbara Neas; Alexis Mathian; Michael N Koss; William Stohl; Susan Kovats; Chaim O Jacob
Journal:  J Immunol       Date:  2009-10-07       Impact factor: 5.422

9.  Murine B cell response to TLR7 ligands depends on an IFN-beta feedback loop.

Authors:  Nathaniel M Green; Amy Laws; Kerstin Kiefer; Liliana Busconi; You-Me Kim; Melanie M Brinkmann; Erin Hodges Trail; Kei Yasuda; Sean R Christensen; Mark J Shlomchik; Stefanie Vogel; John H Connor; Hidde Ploegh; Dan Eilat; Ian R Rifkin; Jean Maguire van Seventer; Ann Marshak-Rothstein
Journal:  J Immunol       Date:  2009-07-08       Impact factor: 5.422

10.  Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus.

Authors:  Donna L Thibault; Kareem L Graham; Lowen Y Lee; Imelda Balboni; Paul J Hertzog; Paul J Utz
Journal:  Arthritis Res Ther       Date:  2009-07-22       Impact factor: 5.156

View more
  34 in total

Review 1.  Interferon-γ and systemic autoimmunity.

Authors:  Kenneth M Pollard; David M Cauvi; Christopher B Toomey; Kevin V Morris; Dwight H Kono
Journal:  Discov Med       Date:  2013-09       Impact factor: 2.970

2.  TLR9 Deficiency Leads to Accelerated Renal Disease and Myeloid Lineage Abnormalities in Pristane-Induced Murine Lupus.

Authors:  Lukas Bossaller; Anette Christ; Karin Pelka; Kerstin Nündel; Ping-I Chiang; Catherine Pang; Neha Mishra; Patricia Busto; Ramon G Bonegio; Reinhold Ernst Schmidt; Eicke Latz; Ann Marshak-Rothstein
Journal:  J Immunol       Date:  2016-06-27       Impact factor: 5.422

3.  Fas ligand promotes an inducible TLR-dependent model of cutaneous lupus-like inflammation.

Authors:  Purvi Mande; Bahar Zirak; Wei-Che Ko; Keyon Taravati; Karen L Bride; Tia Y Brodeur; April Deng; Karen Dresser; Zhaozhao Jiang; Rachel Ettinger; Katherine A Fitzgerald; Michael D Rosenblum; John E Harris; Ann Marshak-Rothstein
Journal:  J Clin Invest       Date:  2018-06-11       Impact factor: 14.808

4.  TLR7-Mediated Lupus Nephritis Is Independent of Type I IFN Signaling.

Authors:  Sonya J Wolf; Jonathan Theros; Tammi J Reed; Jianhua Liu; Irina L Grigorova; Giovanny Martínez-Colón; Chaim O Jacob; Jeffrey B Hodgin; J Michelle Kahlenberg
Journal:  J Immunol       Date:  2018-06-08       Impact factor: 5.422

Review 5.  Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE.

Authors:  Thomas Dörner; Peter E Lipsky
Journal:  Nat Rev Rheumatol       Date:  2016-10-13       Impact factor: 20.543

Review 6.  Contributions of B cells to lupus pathogenesis.

Authors:  Allison Sang; Ying-Yi Zheng; Laurence Morel
Journal:  Mol Immunol       Date:  2013-12-12       Impact factor: 4.407

7.  Cell-intrinsic expression of TLR9 in autoreactive B cells constrains BCR/TLR7-dependent responses.

Authors:  Kerstin Nündel; Nathaniel M Green; Arthur L Shaffer; Krishna L Moody; Patricia Busto; Dan Eilat; Kensuke Miyake; Michael A Oropallo; Michael P Cancro; Ann Marshak-Rothstein
Journal:  J Immunol       Date:  2015-02-13       Impact factor: 5.422

Review 8.  Apoptotic cell responses in the splenic marginal zone: a paradigm for immunologic reactions to apoptotic antigens with implications for autoimmunity.

Authors:  Tracy L McGaha; Mikael C I Karlsson
Journal:  Immunol Rev       Date:  2016-01       Impact factor: 12.988

9.  Lupus and proliferative nephritis are PAD4 independent in murine models.

Authors:  Rachael A Gordon; Jan M Herter; Florencia Rosetti; Allison M Campbell; Hiroshi Nishi; Michael Kashgarian; Sheldon I Bastacky; Anthony Marinov; Kevin M Nickerson; Tanya N Mayadas; Mark J Shlomchik
Journal:  JCI Insight       Date:  2017-05-18

10.  Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice.

Authors:  Jason S Knight; Venkataraman Subramanian; Alexander A O'Dell; Srilakshmi Yalavarthi; Wenpu Zhao; Carolyne K Smith; Jeffrey B Hodgin; Paul R Thompson; Mariana J Kaplan
Journal:  Ann Rheum Dis       Date:  2014-08-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.